论文部分内容阅读
目的：探讨低分子肝素（商品名速避凝，Ｆｒａ）辅助治疗急性心肌梗死（ＡＭＩ）的疗效及安全性。方法：将７１例ＡＭＩ患者随机单盲分为３组：在ＡＭＩ常规治疗的基础上，Ａ组加用阿司匹林（ＡＳＡ），Ｂ组加用噻氯匹定（商品名力抗栓，ＴＰ），Ｃ组加用速避凝和力抗栓。结果：住院期间，Ｃ组梗死后发生心绞痛（ＡＰ）频率、静滴硝酸甘油（ＮＧ）剂量、用镇痛药次数明显比Ａ组及Ｂ组减少（Ｐ＜０．０１），且心脏左室射血分数（ＬＶＥＦ）和快速充盈期与心房收缩期二尖瓣口血流比（Ｅ／Ａ）改善均优于Ａ组（Ｐ＜０．０１）和Ｂ组（Ｐ＜０．０５），心脑事件也有减少趋势。随访１年，Ｃ组发生不稳定型心绞痛（ＵＳＡＰ）、心力衰竭、心律失常远较Ａ组（Ｐ＜０．０１）及Ｂ组（Ｐ＜０．０５）少，再发梗死（再梗）比Ａ组和Ｂ组分别减少８０％及５０％、心性死亡比Ａ组减少６７％。结论：速避凝有强力的抗血栓作用，加用力抗栓治疗ＡＭＩ患者，为可降低再梗及心脑事件发生的二级预防药物，不良反应少，疗效安全可靠，值得推广应用
Objective: To investigate the efficacy and safety of low molecular weight heparin (Fra) in adjuvant treatment of acute myocardial infarction (AMI). Methods: A total of 71 patients with AMI were randomly divided into 3 groups according to the routine treatment: AMI was given aspirin (ASA) in group A, ticlopidine (TP) was used in group B, C group plus speed condensate and force antithrombotic. Results: During hospitalization, the frequency of angina pectoris (AP), the dose of intravenous nitroglycerin (NG), the number of analgesic drugs in group C were significantly lower than those in group A and group B (P <0.01) The ejection fraction (LVEF), mitral inflow velocity (E / A) in fast filling phase and atrial systole were significantly better than those in group A (P <0.01) and group B (P <0.05) Cardiovascular events also have a decreasing trend. After one year of follow-up, unstable angina pectoris (USAP), heart failure, arrhythmia were much less in group C than in group A (P <0.01) and group B (P <0.05) 80% and 50% less than those in group A and group B, respectively, and 67% less than in group A. CONCLUSION: Anesthetizing and antithrombotic therapy with strong antithrombotic effect and force and antithrombotic therapy are secondary prevention drugs that can reduce the occurrence of re-infarction and cardio-cerebral events with less adverse reactions and safe and reliable curative effect, which is worthy of promotion and application